Home > Knowledge > Content
Use of tranexamic acid and synthesis method
Jun 11, 2018

Methiculic acid is a derivative of amino toluic acid. It is an anti fibrinolytic hemostatic drug. The hemostatic mechanism is the same as aminohexanic acid and amino toluic acid, but the effect is stronger. The strength is 7~10 times of aminohexanic acid and 2 times of aminotoluic acid, and the toxicity is similar.

The chemical structure of methicinic acid is similar to that of lysine. It can inhibit the adsorption of fibrinogen on fibrinogen, prevent its activation, protect fibrin from degradation and dissolution of fibrinolytic enzyme, and finally achieve hemostatic effect. It is suitable for the treatment of acute or chronic, localized or systemic primary fibrinolytic hyperhypersplenism, such as obstetric bleeding, renal hemorrhage, hypertrophy of the prostate, hemophilia, pulmonary tuberculosis, gastric hemorrhage, liver, lung, spleen and other visceral bleeding, etc., and abnormal bleeding during the operation.

Clinical effects of methicyclic acid on insect bite, eczema dermatitis, simple purpura, chronic urticaria, artificial urticaria, toxic rash and drug rash are significant. It also has a certain effect on erythroderma, scleroderma, SLE, erythema multiform, herpes zoster and alopecia alopecia, and has a good effect on hereditary vascular edema. Treatment of chloasma generally took 3 weeks, effective 5 weeks, 60 d a course of treatment. 0.25 to 0.5g each time, 3~4 times a day. A few patients can experience side effects such as nausea, fatigue, itching, abdominal discomfort and diarrhea, and disappear after withdrawal.